We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
How Hologic Leverages Its Financial Firepower to Drive Long-Term Value
Read MoreHide Full Article
Key Takeaways
HOLX uses steady cash flow to fund acquisitions and repurchase shares, boosting shareholder value.
HOLX's recent acquisitions show faster growth than legacy units and help lift operating margins.
Strong liquidity and low debt allow HOLX to continue funding growth through acquisitions and buybacks.
Hologic’s (HOLX - Free Report) consistent profitability has led to strong cash flow generation, approximately $1 billion annually, supporting the development of a pristine balance sheet. The company’s capital deployment strategy prioritizes tuck-in acquisitions to access high-growth adjacent markets, followed by share repurchases, mainly to manage dilution and, if needed, to narrow the gap in double-digit earnings. In recent years, Hologic has allocated approximately $3.6 billion on share repurchases, including $200 million in the second quarter of fiscal 2025, and another $2 billion on M&A.
Notable acquisitions include Biotheranostics in the Diagnostics division, Endomagnetics in Breast Health and, most recently, Gynesonics in Surgical. These businesses are growing faster than Hologic’s legacy units, and their integration into the portfolios is set to drive the company’s operating margins toward the corporate average. As of the second-quarter end, Hologic had $1.6 billion in cash and investments and a leverage position below 1X, holding ample financial capacity to continue both inorganic investments and buybacks.
All three acquisitions are expected to boost the company’s revenue growth rate. Biotheranostics is seeing increased lab testing volumes from the growing adoption of the Breast Cancer Index test, which helps assess the benefits of continued endocrine therapy. Endomagnetics is currently enjoying strong momentum, with its market-leading products and R&D capabilities highly complementing Hologic’s interventional breast portfolio. In the second quarter of fiscal 2025, Hologic started selling Endomagnetics products directly through its North American salesforce — a strategic action led by the company’s new leadership, positioning it to capture the significant market opportunity in wireless localization.
Meanwhile, Gynesonics has expanded the Surgical portfolio with the Sonata System, a minimally invasive radio frequency ablation tool that treats uterine fibroids less accessible by MyoSure or Accesa. The addition is expected to amplify the strength of Hologic’s International Surgical business.
Scenario for Hologic’s Rivals
Becton, Dickinson and Company (BDX - Free Report) , or BD, on its May 2025 earnings call, reported year-to-date free cash flows of approximately $625 million, impacted byplanned one-time cash payments. BD’s net leverage stood at 2.9X, in line with its expectations, and the company has already repurchased $750 million so far, with the goal of deploying $1 billion by year-end.
Thermo Fisher Scientific (TMO - Free Report) reported $370 million in free cash flow in the first quarter of 2025. Thermo Fisher returned $2.1 billion of capital to shareholders through $2 billion of share buybacks, completed in January, and approximately $150 million of dividends. Further, TMO announced plans to acquire Solventum's purification and filtration business for approximately $4.1 billion in cash.
HOLX Stock Performance, Valuation and Estimates
In the past three months, Hologic shares have risen 5.3% against the industry’s 8.6% fall.
Image Source: Zacks Investment Research
Hologic sits at a favorable position relative to the industry with a forward two-year earnings multiple of 14.66X. The stock carries a Value Score of B at present.
Image Source: Zacks Investment Research
Here’s how consensus estimates for Hologic’s fiscal 2025 and 2026 earnings are shaping up.
Image Source: Zacks Investment Research
HOLX stock currently carries a Zacks Rank #4 (Sell).
Image: Bigstock
How Hologic Leverages Its Financial Firepower to Drive Long-Term Value
Key Takeaways
Hologic’s (HOLX - Free Report) consistent profitability has led to strong cash flow generation, approximately $1 billion annually, supporting the development of a pristine balance sheet. The company’s capital deployment strategy prioritizes tuck-in acquisitions to access high-growth adjacent markets, followed by share repurchases, mainly to manage dilution and, if needed, to narrow the gap in double-digit earnings. In recent years, Hologic has allocated approximately $3.6 billion on share repurchases, including $200 million in the second quarter of fiscal 2025, and another $2 billion on M&A.
Notable acquisitions include Biotheranostics in the Diagnostics division, Endomagnetics in Breast Health and, most recently, Gynesonics in Surgical. These businesses are growing faster than Hologic’s legacy units, and their integration into the portfolios is set to drive the company’s operating margins toward the corporate average. As of the second-quarter end, Hologic had $1.6 billion in cash and investments and a leverage position below 1X, holding ample financial capacity to continue both inorganic investments and buybacks.
All three acquisitions are expected to boost the company’s revenue growth rate. Biotheranostics is seeing increased lab testing volumes from the growing adoption of the Breast Cancer Index test, which helps assess the benefits of continued endocrine therapy. Endomagnetics is currently enjoying strong momentum, with its market-leading products and R&D capabilities highly complementing Hologic’s interventional breast portfolio. In the second quarter of fiscal 2025, Hologic started selling Endomagnetics products directly through its North American salesforce — a strategic action led by the company’s new leadership, positioning it to capture the significant market opportunity in wireless localization.
Meanwhile, Gynesonics has expanded the Surgical portfolio with the Sonata System, a minimally invasive radio frequency ablation tool that treats uterine fibroids less accessible by MyoSure or Accesa. The addition is expected to amplify the strength of Hologic’s International Surgical business.
Scenario for Hologic’s Rivals
Becton, Dickinson and Company (BDX - Free Report) , or BD, on its May 2025 earnings call, reported year-to-date free cash flows of approximately $625 million, impacted byplanned one-time cash payments. BD’s net leverage stood at 2.9X, in line with its expectations, and the company has already repurchased $750 million so far, with the goal of deploying $1 billion by year-end.
Thermo Fisher Scientific (TMO - Free Report) reported $370 million in free cash flow in the first quarter of 2025. Thermo Fisher returned $2.1 billion of capital to shareholders through $2 billion of share buybacks, completed in January, and approximately $150 million of dividends. Further, TMO announced plans to acquire Solventum's purification and filtration business for approximately $4.1 billion in cash.
HOLX Stock Performance, Valuation and Estimates
In the past three months, Hologic shares have risen 5.3% against the industry’s 8.6% fall.
Image Source: Zacks Investment Research
Hologic sits at a favorable position relative to the industry with a forward two-year earnings multiple of 14.66X. The stock carries a Value Score of B at present.
Image Source: Zacks Investment Research
Here’s how consensus estimates for Hologic’s fiscal 2025 and 2026 earnings are shaping up.
Image Source: Zacks Investment Research
HOLX stock currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.